TENAX THERAPEUTICS, INC. Available-for-sale Securities, Gross Unrealized Gain
TENAX THERAPEUTICS, INC. (TENX) reported Available-for-sale Securities, Gross Unrealized Gain of $46 for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains · last filed 2021-08-16
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2021-06-30 was $15.00, a 99.12% decline year-over-year.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2021-03-31 was $31.00, a 92.69% decline year-over-year.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2020-12-31 was -$865.00.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2020-09-30 was -$1.13K.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized gain for fiscal 2020 was $128.00, a 76.94% decline from fiscal 2019.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized gain for fiscal 2019 was $555.00, a 11.34% decline from fiscal 2018.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized gain for fiscal 2018 was $626.00.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized gain for fiscal 2015 was $46.16K.
| Period end | Available-for-sale Securities, Gross Unrealized Gain 3 month | Available-for-sale Securities, Gross Unrealized Gain 6 month | Available-for-sale Securities, Gross Unrealized Gain 9 month | Available-for-sale Securities, Gross Unrealized Gain 12 month |
|---|---|---|---|---|
| 2021-06-30 | $15.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $46.00 10-Q · filed 2021-08-16 | -$819.00 derived: sum of 3 quarters · filed 2021-08-16 | -$1.95K derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | $31.00 10-Q · filed 2021-05-17 | -$834.00 derived: sum of 2 quarters · filed 2021-05-17 | -$1.97K derived: sum of 3 quarters · filed 2021-05-17 | -$265.00 derived: sum of 4 quarters · filed 2021-05-17 |
| 2020-12-31 | -$865.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-16 | -$2.00K derived: sum of 2 quarters · filed 2021-04-16 | -$296.00 derived: sum of 3 quarters · filed 2021-04-16 | $128.00 10-K/A · filed 2021-04-16 |
| 2020-09-30 | -$1.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $569.00 derived: sum of 2 quarters · filed 2020-11-16 | $993.00 10-Q · filed 2020-11-16 | $211.00 derived: sum of 4 quarters · filed 2020-11-16 |
| 2020-06-30 | $1.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $2.13K 10-Q · filed 2020-08-14 | $1.34K derived: sum of 3 quarters · filed 2020-08-14 | $399.00 derived: sum of 4 quarters · filed 2020-08-14 |
| 2020-03-31 | $424.00 10-Q · filed 2020-05-15 | -$358.00 derived: sum of 2 quarters · filed 2020-05-15 | -$1.30K derived: sum of 3 quarters · filed 2020-05-15 | -$890.00 derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-12-31 | -$782.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$1.73K derived: sum of 2 quarters · filed 2020-03-30 | -$1.31K derived: sum of 3 quarters · filed 2020-03-30 | $555.00 10-K · filed 2020-03-30 |
| 2019-09-30 | -$944.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$532.00 derived: sum of 2 quarters · filed 2019-11-14 | $1.34K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $412.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $2.28K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $1.87K 10-Q · filed 2019-05-15 | |||
| 2018-12-31 | $626.00 10-K · filed 2019-04-01 | |||
| 2015-07-31 | $375.00 10-Q · filed 2015-09-09 | -$40.19K derived: sum of 2 quarters · filed 2015-09-09 | $25.52K derived: sum of 3 quarters · filed 2015-09-09 | $45.62K derived: sum of 4 quarters · filed 2015-09-09 |
| 2015-04-30 | -$40.57K derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-14 | $25.14K derived: sum of 2 quarters · filed 2015-07-14 | $45.25K derived: sum of 3 quarters · filed 2015-07-14 | $46.16K 10-K · filed 2015-07-14 |
| 2015-01-31 | $65.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-03-17 | $85.81K derived: sum of 2 quarters · filed 2015-03-17 | $86.72K 10-Q · filed 2015-03-17 | |
| 2014-10-31 | $20.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-15 | $21.01K 10-Q · filed 2014-12-15 | ||
| 2014-07-31 | $910.00 10-Q · filed 2014-09-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |